[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332852-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332852-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","role-of-solute-carrier-transporters-in-ovarian-cancer-review","Role of solute carrier transporters in ovarian cancer - Review","","Solute carrier (SLC) transporters participate in metabolic reprogramming and cancer-related processes, supporting higher nutrient and energy demands. Advances over the past decade clarify how SLC expression and function contribute to ovarian cancer, a disease with high mortality and limited therapies, where early diagnosis remains challenging. Ovarian cancer shows complexity and heterogeneity, influencing clinical behavior, chemotherapy resistance, and prognosis. Distinct SLC expression patterns between healthy and tumor tissues suggest that modulating SLC activity can alter signaling pathways driving proliferation, apoptosis, and drug accumulation. This review consolidates current evidence and highlights opportunities to use SLCs as prognostic biomarkers and therapeutic targets.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/role-of-solute-carrier-transporters-in-ovarian-cancer-review/332852/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/role-of-solute-carrier-transporters-in-ovarian-cancer-review/332852.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What roles do solute carrier transporters play in ovarian cancer?","Question",{"text":63,"@type":64},"SLC transporters contribute to metabolic reprogramming and cancer biology by supporting increased nutrient/energy requirements. Their altered expression may affect signaling pathways involved in proliferation, apoptosis, and drug accumulation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is early diagnosis considered a clinical target in ovarian cancer?",{"text":68,"@type":64},"Ovarian cancer has a high mortality rate and limited treatment options. The review notes that early diagnosis is still a target clinically.",{"name":70,"@type":61,"acceptedAnswer":71},"How could SLCs be used beyond being studied in ovarian cancer biology?",{"text":72,"@type":64},"The review aims to consolidate data and provide guidance for further research using SLCs as prognostic biomarkers and as therapeutic targets.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332852,1790156653,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE 55: 24, 2025  \nRole of solute carrier transporters in ovarian cancer (Review)  \nBARBARA QUARESIMA, STEFANIA ScIccHITANO, MARIA cONcETTAFANIELLO* and MARIA MESURAcA*  \nDepartment of Experimental and Clinical Medicine,‘Magna Graecia’University of Catanzaro, I‑88100 Catanzaro, Italy  \nReceived August 23, 2024; Accepted October 11, 2024  \ndOI: 10.3892/ijmm.2024.5465  \nAbstract. Solute carrier (SLc) transporters are involved in various biological processes associated with metabolic repro‑ gramming and cancer, supporting the increased requirement of nutrients and energy. Over the past decade, there have been significant advancements in understanding the expression and function of SLcs in ovarian cancer (Oc) . This gynecological condition has a high mortality rate and limited treatment options; thus, early diagnosis remains a target clinically. Oc exhibits complexity and heterogeneity, resulting in different clinical characteristics, resistance to chemotherapy drugs and poor prognosis. Additionally, SLCs have a different expression pattern between healthy and tumor tissue, and consequently, their inhibition or activation could modify signaling pathways involved in the tumor growth process, such as cell prolif‑ eration, apoptosis and drug accumulation. The present review aims to consolidate current data to provide a comprehensive understanding of the potential importance of SLcs in Oc. Additionally, it seeks to offer guidance for further research on utilizing SLcs as prognostic biomarkers and therapeutic targets.  \nContents  \n1. Introduction  \n2. SLCs expressed in OC  \n3. Therapeutic drugs and target genes  \n4. conclusions  \nCorrespondence to: dr Maria Mesuraca or dr Barbara Quaresima, Department of Experimental and Clinical Medicine, ‘Magna Graecia’ University of Catanzaro, Viale Europa, I‑88100 Catanzaro, Italy  \nE‑[mail: mes@unicz.it](mail: mes@unicz.it)  \nE‑mail: [quaresi@unicz.it](quaresi@unicz.it)  \n*contributed equally  \nKey words: solute carrier, transporter, ovarian cancer, signaling pathways, tumorigenesis, drug resistance  \n1. Introduction  \nTransporters are membrane proteins that facilitate the move‑ ment of various substances such as nutrients, neurotransmitters, ions, metabolites and drugs, and are involved in important biological processes including the regulation of cell signaling and the organization of cellular organelles (1). Originally, these membrane proteins were categorized as ATP‑independent transporter proteins, but in 2004 they were classified into two major superfamilies: The ATP‑binding cassette (ABc) and solute carrier (SLc) families (2‑4) .  \nMembrane transporters SLcs, which are more numerous than ABcs, play a crucial role in facilitating communication between the cell and its environment. Genetic variants in the SLc family have been associated with various diseases, including neurological or metabolic disorders and cancer (5,6) . despite their biological importance, SLcs are among the most understudied class of proteins, with >455 membrane‑bound proteins classified into 66 families, for this reason, numerous aspects of their biology remain unknown (7) .  \nThere have been significant advances in the structural biology of membrane proteins, which have greatly improved the understanding of molecular‑level transport (6) . SLc transporters are an extremely diverse family of membrane proteins. The most common structural classes in human SLcs are the LeuT‑like fold leucine transporter (such as SLc6) and the Major Facilitator Superfamily (such as SLc2) (7‑10) . The diversity of SLC proteins is determined by the specificity of the substrate, as well as the different regulatory properties and tissue‑ and cell‑type‑specific metabolic requirements (11‑13) .  \nOvarian cancer (Oc) is a gynecological pathology with a high mortality rate, often diagnosed at an advanced stage, leading to a poor prognosis (14). The main response at the onset of the disease is instrumental scree","cbCaigbITvx5aW3k","https://ap.wps.com/l/cbCaigbITvx5aW3k","pdf",2083156,"English","# Introduction\n## SLCs expressed in OC\n## Therapeutic drugs and target genes\n## Conclusions","[{\"question\":\"What roles do solute carrier transporters play in ovarian cancer?\",\"answer\":\"SLC transporters contribute to metabolic reprogramming and cancer biology by supporting increased nutrient/energy requirements. Their altered expression may affect signaling pathways involved in proliferation, apoptosis, and drug accumulation.\"},{\"question\":\"Why is early diagnosis considered a clinical target in ovarian cancer?\",\"answer\":\"Ovarian cancer has a high mortality rate and limited treatment options. The review notes that early diagnosis is still a target clinically.\"},{\"question\":\"How could SLCs be used beyond being studied in ovarian cancer biology?\",\"answer\":\"The review aims to consolidate data and provide guidance for further research using SLCs as prognostic biomarkers and as therapeutic targets.\"}]","Role of solute carrier transporters in ovarian cancer - Review | PDF",1789999762,28]